CCL three-lens brief
Evidence-based stock research on CCL. Three independent lenses — Quality, Momentum, Context — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Underperforming SPY by 18.0pp over 30 days. · Debt-to-equity of 203.9 — balance-sheet-heavy.
- Underperforming SPY by 18.0pp over 30 days.
- P/E of 10.9 — trading at a value multiple.
- Analyst mean target $34.01 — 38% above current (21 analysts).
- Debt-to-equity of 203.9 — balance-sheet-heavy.
CCL closed at $24.68 (-0.70%) as of 2026-05-13. Market cap: $34.18B. P/E (trailing) 10.9. Positives: p/E of 10.9 — trading at a value multiple.; analyst mean target $34.01 — 38% above current (21 analysts).. Concerns: underperforming SPY by 18.0pp over 30 days.; debt-to-equity of 203.9 — balance-sheet-heavy.. Last quarter: Revenue $6.17B, net income $258.00M, free cash flow $2.17B.
Why three lenses on CCL, not one.
A single reasoning model has blind spots it doesn’t know about. We examine CCLacross Quality (fundamentals), Momentum (price action and sentiment), and Context (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/CCL" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath CCL brief"></iframe>